Exhibits
8-K
from 8-K
7 pages
8-K
11/18/24
EX-10.1
from 8-K
36 pages
Securities Purchase Agreement
11/18/24
EX-10.2
from 8-K
15 pages
Registration Rights Agreement
11/18/24
EX-10.3
from 8-K
18 pages
Employment Agreement
11/18/24
EX-10.4
from 8-K
20 pages
Aclaris Therapeutics, Inc. 2024 Inducement Plan Adopted by the Board of Directors: November 16, 2024
11/18/24
EX-10.5
from 8-K
12 pages
Aclaris Therapeutics, Inc. 2024 Inducement Plan Stock Option Grant Notice
11/18/24
EX-10.6
from 8-K
11 pages
Aclaris Therapeutics, Inc. Restricted Stock Unit Grant Notice
11/18/24
EX-99.1
from 8-K
3 pages
Aclaris Therapeutics Announces Exclusive, Global License Agreement With Biosion, Inc., Adding Potential Best-In-Class Biologics Assets to Pipeline
11/18/24
EX-99.2
from 8-K
2 pages
Aclaris Therapeutics Announces $80 Million Private Placement
11/18/24
EX-99.3
from 8-K
35 pages
© Copyright 2024 Aclaris Therapeutics, Inc. All Rights Reserved Confidential © Copyright 2024 Aclaris Therapeutics, Inc. All Rights Reserved Corporate Overview November 2024
11/18/24
Graphics & Data Files
GRAPHIC
from 8-K
acrs-20241116xex99d1001.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d2001.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g001.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g002.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g003.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g004.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g005.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g006.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g007.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g008.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g009.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g010.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g011.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g012.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g013.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g014.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g015.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g016.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g017.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g018.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g019.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g020.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g021.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g022.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g023.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g024.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g025.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g026.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g027.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g028.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g029.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g030.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g031.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g032.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g033.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g034.jpg
11/18/24
GRAPHIC
from 8-K
acrs-20241116xex99d3g035.jpg
11/18/24
